A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs ELX 02 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eloxx Pharmaceuticals
- 03 Dec 2019 Planned End Date changed from 1 Feb 2020 to 15 Jun 2020.
- 03 Dec 2019 Planned primary completion date changed from 1 Jan 2020 to 15 May 2020.
- 05 Nov 2019 According to an Eloxx Pharmaceuticals media release, the company is actively enrolling patients in Israel and expect to open European sites this quarter.